clinical trial · NCT06375993
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Lupus NephritisAutoimmune DiseasesSystemic Sclerosis (SSc)Systemic Lupus Erythematosus (SLE)ANCA-Associated Vasculitis (AAV)Idiopathic Inflammatory MyopathiesStiff Person SyndromeADI-001FludarabineCyclophosphamide
brief summary
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up
started
Nov 10, 2024
primary completion
Dec 1, 2026
completion
Dec 1, 2027
last updated
Mar 19, 2026
official title
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Autoimmune Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol